

Amendments

In the Specification:

Please replace the priority information, below the title on page 1, with the following priority information:

B1
This application is a 35 U.S.C. § 371 national stage application of the international application, PCT/EP98/07682, filed November 27, 1998, and published in German as WO 99/28499 on June 10, 1999, which claims priority benefit to German application no. 197 52 922.4 filed November 28, 1997 and German application no. 198 05 229.4, filed February 10, 1998.

In the Claims:

Please replace pending claims 29-31 and 35-37 with the following claims 29-31 and 35-37:

mb c8
29. The method of claim 28, wherein the dominant negative receptor is the Insulin-like Growth Factor-1 (IGF-1) receptor.

B2
30. The method of claim 28, wherein the dominant negative receptor is the Fibroblast Growth Factor (FGF) receptor.

31. The method of claim 28, wherein the dominant negative receptor is the Platelet Derived Growth Factor (PDGF) receptor.